Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients

Bih Rong Wei, Shelley B. Hoover, Mark M. Ross, Weidong Zhou, Francesco Meani, Jeniffer B. Edwards, Elizabeth I. Spehalski, John I. Risinger, W. Gregory Alvord, Octavio A. Quiñones, Claudio Belluco, Luca Martella, Elio Campagnutta, Antonella Ravaggi, Rei Ming Dai, Paul K. Goldsmith, Kevin D Woolard, Sergio Pecorelli, Lance A. Liotta, Emanuel F. PetricoinR. Mark Simpson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Ovarian cancer is the 5th leading cause of cancer related deaths in women. Five-year survival rates for early stage disease are greater than 94%, however most women are diagnosed in advanced stage with 5 year survival less than 28%. Improved means for early detection and reliable patient monitoring are needed to increase survival. Methodology and Principal Findings: Applying mass spectrometry-based proteomics, we sought to elucidate an unanswered biomarker research question regarding ability to determine tumor burden detectable by an ovarian cancer biomarker protein emanating directly from the tumor cells. Since aggressive serous epithelial ovarian cancers account for most mortality, a xenograft model using human SKOV-3 serous ovarian cancer cells was established to model progression to disseminated carcinomatosis. Using a method for low molecular weight protein enrichment, followed by liquid chromatography and mass spectrometry analysis, a human-specific peptide sequence of S100A6 was identified in sera from mice with advanced-stage experimental ovarian carcinoma. S100A6 expression was documented in cancer xenografts as well as from ovarian cancer patient tissues. Longitudinal study revealed that serum S100A6 concentration is directly related to tumor burden predictions from an inverse regression calibration analysis of data obtained from a detergentsupplemented antigen capture immunoassay and whole-animal bioluminescent optical imaging. The result from the animal model was confirmed in human clinical material as S100A6 was found to be significantly elevated in the sera from women with advanced stage ovarian cancer compared to those with early stage disease. Conclusions: S100A6 is expressed in ovarian and other cancer tissues, but has not been documented previously in ovarian cancer disease sera. S100A6 is found in serum in concentrations that correlate with experimental tumor burden and with clinical disease stage. The data signify that S100A6 may prove useful in detecting and/or monitoring ovarian cancer, when used in concert with other biomarkers.

Original languageEnglish (US)
Article numbere7670
JournalPLoS One
Volume4
Issue number10
DOIs
StatePublished - Oct 30 2009
Externally publishedYes

Fingerprint

ovarian neoplasms
Tumor Burden
Ovarian Neoplasms
Tumors
neoplasms
mice
Biomarkers
Serum
Heterografts
Mass spectrometry
Animals
Cells
Tissue
Patient monitoring
biomarkers
Liquid chromatography
Tumor Biomarkers
Mass Spectrometry
Proteins
Molecular weight

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. / Wei, Bih Rong; Hoover, Shelley B.; Ross, Mark M.; Zhou, Weidong; Meani, Francesco; Edwards, Jeniffer B.; Spehalski, Elizabeth I.; Risinger, John I.; Alvord, W. Gregory; Quiñones, Octavio A.; Belluco, Claudio; Martella, Luca; Campagnutta, Elio; Ravaggi, Antonella; Dai, Rei Ming; Goldsmith, Paul K.; Woolard, Kevin D; Pecorelli, Sergio; Liotta, Lance A.; Petricoin, Emanuel F.; Simpson, R. Mark.

In: PLoS One, Vol. 4, No. 10, e7670, 30.10.2009.

Research output: Contribution to journalArticle

Wei, BR, Hoover, SB, Ross, MM, Zhou, W, Meani, F, Edwards, JB, Spehalski, EI, Risinger, JI, Alvord, WG, Quiñones, OA, Belluco, C, Martella, L, Campagnutta, E, Ravaggi, A, Dai, RM, Goldsmith, PK, Woolard, KD, Pecorelli, S, Liotta, LA, Petricoin, EF & Simpson, RM 2009, 'Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients', PLoS One, vol. 4, no. 10, e7670. https://doi.org/10.1371/journal.pone.0007670
Wei, Bih Rong ; Hoover, Shelley B. ; Ross, Mark M. ; Zhou, Weidong ; Meani, Francesco ; Edwards, Jeniffer B. ; Spehalski, Elizabeth I. ; Risinger, John I. ; Alvord, W. Gregory ; Quiñones, Octavio A. ; Belluco, Claudio ; Martella, Luca ; Campagnutta, Elio ; Ravaggi, Antonella ; Dai, Rei Ming ; Goldsmith, Paul K. ; Woolard, Kevin D ; Pecorelli, Sergio ; Liotta, Lance A. ; Petricoin, Emanuel F. ; Simpson, R. Mark. / Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. In: PLoS One. 2009 ; Vol. 4, No. 10.
@article{b3cc1b7a12b84b669488bef3912b7c1c,
title = "Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients",
abstract = "Background: Ovarian cancer is the 5th leading cause of cancer related deaths in women. Five-year survival rates for early stage disease are greater than 94{\%}, however most women are diagnosed in advanced stage with 5 year survival less than 28{\%}. Improved means for early detection and reliable patient monitoring are needed to increase survival. Methodology and Principal Findings: Applying mass spectrometry-based proteomics, we sought to elucidate an unanswered biomarker research question regarding ability to determine tumor burden detectable by an ovarian cancer biomarker protein emanating directly from the tumor cells. Since aggressive serous epithelial ovarian cancers account for most mortality, a xenograft model using human SKOV-3 serous ovarian cancer cells was established to model progression to disseminated carcinomatosis. Using a method for low molecular weight protein enrichment, followed by liquid chromatography and mass spectrometry analysis, a human-specific peptide sequence of S100A6 was identified in sera from mice with advanced-stage experimental ovarian carcinoma. S100A6 expression was documented in cancer xenografts as well as from ovarian cancer patient tissues. Longitudinal study revealed that serum S100A6 concentration is directly related to tumor burden predictions from an inverse regression calibration analysis of data obtained from a detergentsupplemented antigen capture immunoassay and whole-animal bioluminescent optical imaging. The result from the animal model was confirmed in human clinical material as S100A6 was found to be significantly elevated in the sera from women with advanced stage ovarian cancer compared to those with early stage disease. Conclusions: S100A6 is expressed in ovarian and other cancer tissues, but has not been documented previously in ovarian cancer disease sera. S100A6 is found in serum in concentrations that correlate with experimental tumor burden and with clinical disease stage. The data signify that S100A6 may prove useful in detecting and/or monitoring ovarian cancer, when used in concert with other biomarkers.",
author = "Wei, {Bih Rong} and Hoover, {Shelley B.} and Ross, {Mark M.} and Weidong Zhou and Francesco Meani and Edwards, {Jeniffer B.} and Spehalski, {Elizabeth I.} and Risinger, {John I.} and Alvord, {W. Gregory} and Qui{\~n}ones, {Octavio A.} and Claudio Belluco and Luca Martella and Elio Campagnutta and Antonella Ravaggi and Dai, {Rei Ming} and Goldsmith, {Paul K.} and Woolard, {Kevin D} and Sergio Pecorelli and Liotta, {Lance A.} and Petricoin, {Emanuel F.} and Simpson, {R. Mark}",
year = "2009",
month = "10",
day = "30",
doi = "10.1371/journal.pone.0007670",
language = "English (US)",
volume = "4",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients

AU - Wei, Bih Rong

AU - Hoover, Shelley B.

AU - Ross, Mark M.

AU - Zhou, Weidong

AU - Meani, Francesco

AU - Edwards, Jeniffer B.

AU - Spehalski, Elizabeth I.

AU - Risinger, John I.

AU - Alvord, W. Gregory

AU - Quiñones, Octavio A.

AU - Belluco, Claudio

AU - Martella, Luca

AU - Campagnutta, Elio

AU - Ravaggi, Antonella

AU - Dai, Rei Ming

AU - Goldsmith, Paul K.

AU - Woolard, Kevin D

AU - Pecorelli, Sergio

AU - Liotta, Lance A.

AU - Petricoin, Emanuel F.

AU - Simpson, R. Mark

PY - 2009/10/30

Y1 - 2009/10/30

N2 - Background: Ovarian cancer is the 5th leading cause of cancer related deaths in women. Five-year survival rates for early stage disease are greater than 94%, however most women are diagnosed in advanced stage with 5 year survival less than 28%. Improved means for early detection and reliable patient monitoring are needed to increase survival. Methodology and Principal Findings: Applying mass spectrometry-based proteomics, we sought to elucidate an unanswered biomarker research question regarding ability to determine tumor burden detectable by an ovarian cancer biomarker protein emanating directly from the tumor cells. Since aggressive serous epithelial ovarian cancers account for most mortality, a xenograft model using human SKOV-3 serous ovarian cancer cells was established to model progression to disseminated carcinomatosis. Using a method for low molecular weight protein enrichment, followed by liquid chromatography and mass spectrometry analysis, a human-specific peptide sequence of S100A6 was identified in sera from mice with advanced-stage experimental ovarian carcinoma. S100A6 expression was documented in cancer xenografts as well as from ovarian cancer patient tissues. Longitudinal study revealed that serum S100A6 concentration is directly related to tumor burden predictions from an inverse regression calibration analysis of data obtained from a detergentsupplemented antigen capture immunoassay and whole-animal bioluminescent optical imaging. The result from the animal model was confirmed in human clinical material as S100A6 was found to be significantly elevated in the sera from women with advanced stage ovarian cancer compared to those with early stage disease. Conclusions: S100A6 is expressed in ovarian and other cancer tissues, but has not been documented previously in ovarian cancer disease sera. S100A6 is found in serum in concentrations that correlate with experimental tumor burden and with clinical disease stage. The data signify that S100A6 may prove useful in detecting and/or monitoring ovarian cancer, when used in concert with other biomarkers.

AB - Background: Ovarian cancer is the 5th leading cause of cancer related deaths in women. Five-year survival rates for early stage disease are greater than 94%, however most women are diagnosed in advanced stage with 5 year survival less than 28%. Improved means for early detection and reliable patient monitoring are needed to increase survival. Methodology and Principal Findings: Applying mass spectrometry-based proteomics, we sought to elucidate an unanswered biomarker research question regarding ability to determine tumor burden detectable by an ovarian cancer biomarker protein emanating directly from the tumor cells. Since aggressive serous epithelial ovarian cancers account for most mortality, a xenograft model using human SKOV-3 serous ovarian cancer cells was established to model progression to disseminated carcinomatosis. Using a method for low molecular weight protein enrichment, followed by liquid chromatography and mass spectrometry analysis, a human-specific peptide sequence of S100A6 was identified in sera from mice with advanced-stage experimental ovarian carcinoma. S100A6 expression was documented in cancer xenografts as well as from ovarian cancer patient tissues. Longitudinal study revealed that serum S100A6 concentration is directly related to tumor burden predictions from an inverse regression calibration analysis of data obtained from a detergentsupplemented antigen capture immunoassay and whole-animal bioluminescent optical imaging. The result from the animal model was confirmed in human clinical material as S100A6 was found to be significantly elevated in the sera from women with advanced stage ovarian cancer compared to those with early stage disease. Conclusions: S100A6 is expressed in ovarian and other cancer tissues, but has not been documented previously in ovarian cancer disease sera. S100A6 is found in serum in concentrations that correlate with experimental tumor burden and with clinical disease stage. The data signify that S100A6 may prove useful in detecting and/or monitoring ovarian cancer, when used in concert with other biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=70449555179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449555179&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0007670

DO - 10.1371/journal.pone.0007670

M3 - Article

C2 - 19888321

AN - SCOPUS:70449555179

VL - 4

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e7670

ER -